Overview of genetic testing in patients with pituitary adenomas

Annales d'Endocrinologie

Volumn 73, Issue 2, 2012, Pages 62-64

  Beckers, Albert ^a   Rostomyan, Liliya ^a   Daly, Adrian F ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; UNCLASSIFIED DRUG;

ADENOMA; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CARNEY COMPLEX; CDKN1B GENE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FAMILIAL ISOLATED PITUITARY ADENOMA; GENE; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPOPHYSIS ADENOMA; MEN1 GENE; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 4; PATIENT ASSESSMENT; PENETRANCE; PRACTICE GUIDELINE; PREVALENCE; PRKAR1A GENE; SYMPTOMATOLOGY;

ADENOMA; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; GENETIC TESTING; HUMANS; PITUITARY NEOPLASMS; YOUNG ADULT;

EID: 84860916286     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.03.028     Document Type: Article

References (22)

1. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775.
2. Fernandez A., Karavitaki N., Wass J.A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2010, 72:377-382.
3. Fontana E., Gaillard R. Epidemiology of pituitary adenoma: results of the first Swiss study. Rev Med Suisse 2009, 5:2172-2174.
4. Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Research Clin Endocrinol Metab 2010, 24:355-370.
5. Vezzosi D., Vignaux O., Dupin N., Bertherat J. Carney complex: clinical and genetic 2010 update. Ann Endocrinol 2010, 71:486-493.
6. Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., Valdes Socin H., Rohmer V., Tamburrano G., et al. Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006, 91:3316-3323.
7. Daly A.F., Tichomirowa M.A., Petrossians P., Heliovaara E., Jaffrain-Rea M.L., Barlier A., et al. Clinical characteristics and therapeutic responses in patients with germline AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010, 95:E373-E383.
8. Daly A.F., Vanbellinghen J.F., Khoo S.K., Jaffrain-Rea M.L., Naves L.A., Guitelman M.A., et al. Aryl hydrocarbon receptor interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 2007, 92:1891-1896.
9. Vierimaa O., Georgitsi M., Lehtonen R., Vahteristo P., Kokko A., Raitila A., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006, 312:1228-1230.
10. Tichomirowa M.A., Barlier A., Daly A.F., Jaffrain-Rea M.L., Ronchi C., Yaneva M., et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol 2011, 165:509-515.
11. Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, et al. Germline AIP Mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 2012.
12. Igreja S., Chahal H.S., King P., Bolger G.B., Srirangalingam U., Guasti L., et al. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 2010, 31:950-960.
13. Brandi M.L., Gagel R.F., Angeli A., Bilezikian J.P., Beck-Peccoz P., Bordi C., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
14. Verges B., Boureille F., Goudet P., Murat A., Beckers A., Sassolas G., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87:457-465.
15. Beckers A., Betea D., Valdes Socin H., Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J Intern Med 2003, 253:599-605.
16. Stratakis C.A., Tichomirowa M.A., Boikos S., Azevedo M.F., Lodish M., Martari M., et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010, 78:457-463.
17. Georgitsi M., Raitila A., Karhu A., van der Luijt R.B., Aalfs C.M., Sane T., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007, 92:3321-3325.
18. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., et al. Germline mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006, 103:15558-15563.
19. Tichomirowa MA, Lee M, Barlier A, Daly AF, Marinoni I, Jaffrain-Rea ML, et al. Cyclin dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds. Endocr Relat Cancer 2012.
20. Bertherat J., Horvath A., Groussin L., Grabar S., Boikos S., Cazabat L., et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab 2009, 94:2085-2091.
21. Madsen H., Borges M.T., Kerr J.M., Lillehei K.O., Kleinschmidt-Demasters B.K. McCune-Albright syndrome: surgical and therapeutic challenges in GH-secreting pituitary adenomas. J Neuro-oncol 2011, 104:215-224.
22. Daly A.F., Tichomirowa M.A., Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract Research Clin Endocrinol Metab 2009, 23:543-554.